Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomised controlled trial
<p>Chronic kidney disease (CKD) is associated with substantial risk of progression to end stage renal disease and vascular events. The non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone, offers cardio-renal protection for people with CKD and diabetes, but there is uncertaint...
Main Authors: | Hobbs, R, McManus, RJ, Taylor, CJ, Jones, NR, Rahman, JK, Wolstenholme, J, Kim, S, Kwon, J, Jones, L, Hirst, JA, Yu, L-M, Mort, S |
---|---|
Other Authors: | BARACK-D Investigators |
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2024
|
Similar Items
-
Quality of life in older adults with chronic kidney disease and transient changes in renal function: findings from the Oxford Renal Cohort
by: Yang, Y, et al.
Published: (2022) -
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
by: Hill, NR, et al.
Published: (2014) -
Diagnosis and management of hypertension in adults: NICE guideline update 2019
by: Jones, NR, et al.
Published: (2020) -
Diagnosis and management of hypertension in adults: NICE guideline update 2019
by: Jones, NR, et al.
Published: (2020) -
Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses
by: Cai, T, et al.
Published: (2021)